Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicadrostat plus empagliflozin in chronic kidney disease: simultaneous vs staggered initiation
2024-518457-42-00Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of vicadrostat and empagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Absolute change in eGFR from baseline to Week 14 and Absolute change in eGFR from baseline to Week 16. Started Aug 2025; status: completed.
02
Drugs
vicadrostatempagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-518457-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518457-42-00.